CELU
Celularity Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
0.80
▼ 0.02 (2.01%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.82
Day high
0.85
Day low
0.73
Volume
26.05K
Market cap
$23.16M
P/E (TTM)
—
52W range
0.56 – 4.01
Trailing performance
Returnvs SPY
1W
+14.94%
+16.3%
1M
+5.26%
+1.5%
3M
-11.01%
-14.1%
6M
-40.74%
-51.8%
YTD
-27.93%
-40.2%
1Y
-78.08%
-98.1%
3Y
-72.41%
-146.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on CELU open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
10.76M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Apr 13, 26 | BRIGIDO STEPHEN Officer |
— | 821 | — | Direct |
| Apr 13, 26 | HARIRI ROBERT J Chief Executive Officer |
— | 3.28K | — | Direct |
| Apr 13, 26 | HAINES JOHN R. Officer |
— | 1.64K | — | Direct |
| Jan 12, 26 | PARKS DIANE L. Director |
STOCK | 30.00K | $0 | Direct |
| Jan 12, 26 | DIAMANDIS PETER Director |
STOCK | 20.39K | $0 | Direct |
| Jan 12, 26 | LING GEOFFREY M. D. Director |
STOCK | 19.23K | $0 | Direct |
| Jan 12, 26 | LEVIEN VINCENT Director |
STOCK | 28.85K | $0 | Direct |
| Dec 29, 25 | PARKS DIANE L. Director |
STOCK | 125.00K | $0 | Direct |
| Dec 29, 25 | DIAMANDIS PETER Director |
STOCK | 125.00K | $0 | Direct |
| Dec 29, 25 | LING GEOFFREY M. D. Director |
STOCK | 125.00K | $0 | Direct |
| Dec 29, 25 | LEVIEN VINCENT Director |
STOCK | 125.00K | $0 | Direct |
| Dec 19, 25 | PARKS DIANE L. Director |
STOCK | 67.42K | $0 | Direct |
| Dec 19, 25 | DIAMANDIS PETER Director |
STOCK | 67.42K | $0 | Direct |
| Dec 19, 25 | LING GEOFFREY M. D. Director |
STOCK | 67.42K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BEERS DAVID C |
Chief Financial Officer | 18.20K | Conversion of Exercise of derivative security |
BERMAN RICHARD JAY |
Director | 67.42K | Stock Award(Grant) |
DIAMANDIS PETER |
Director | 394.15K | Stock Award(Grant) |
HAINES JOHN R. |
Officer | 30.18K | Conversion of Exercise of derivative security |
HARIRI ROBERT J |
Chief Executive Officer | 2.85M | Conversion of Exercise of derivative security |
KEHLER DEAN C |
Director | 303.48K | Stock Award(Grant) |
LEVIEN VINCENT |
Director | 153.85K | Stock Award(Grant) |
LIM KOK THAY |
Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
LING GEOFFREY M. D. |
Director | 256.03K | Stock Award(Grant) |
PARKS DIANE L. |
Director | 520.02K | Stock Award(Grant) |
Fundamentals
Market cap$23.16M
Enterprise value$92.00M
Revenue (TTM)$26.55M
Gross profit$6.48M
EBITDA$-54.01M
Net income$-91.80M
EPS (TTM)$-3.59
Free cash flow$5.38M
Total cash$6.17M
Total debt$74.71M
Book value / share$-1.32
Shares outstanding28.95M
Float18.87M
Short % of float5.87%
Dividend yield—
Beta (5Y)0.54
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.40
PEG ratio—
Price / sales—
Price / book—
EV / revenue3.47
EV / EBITDA-1.70
Gross margin24.39%
Operating margin-492.15%
Profit margin0.00%
Return on equity—
Return on assets-30.93%
Debt / equity—
Current ratio0.15
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $26.55M | $54.22M | $22.77M | $17.98M | — | -51.0% |
| Operating revenue | $26.55M | $54.22M | $22.77M | $17.98M | — | -51.0% |
| Cost of revenue | $20.07M | $14.99M | $16.02M | $19.66M | — | +33.9% |
| Gross profit | $6.48M | $39.23M | $6.75M | -$1.69M | — | -83.5% |
| Research & development | $15.03M | $17.39M | $30.46M | $78.36M | — | -13.6% |
| Selling, general & admin | $51.27M | $58.64M | $50.58M | $66.02M | — | -12.6% |
| Total operating expense | $67.78M | $77.78M | $83.23M | $146.58M | — | -12.9% |
| Operating income | -$61.31M | -$38.55M | -$76.48M | -$148.27M | — | -59.0% |
| Net interest income | -$6.49M | -$5.93M | -$2.69M | $365.00K | — | -9.4% |
| Pre-tax income | -$91.71M | -$57.89M | -$196.28M | $14.21M | — | -58.4% |
| Tax provision | $3.00K | $0 | $10.00K | $13.00K | — | — |
| Net income | -$91.72M | -$57.89M | -$196.29M | $14.19M | — | -58.4% |
| Net income to common | -$91.80M | -$57.89M | -$196.29M | $14.19M | — | -58.6% |
| Basic EPS | — | -2.64 | -11.02 | 1.01 | -14.90 | — |
| Diluted EPS | — | -2.64 | -11.02 | 0.95 | -14.90 | — |
| EBIT | -$84.96M | -$51.63M | -$193.27M | $14.21M | — | -64.6% |
| EBITDA | -$77.66M | -$43.71M | -$183.95M | $23.64M | — | -77.7% |
| Basic shares | — | 21.89M | 17.81M | 13.99M | 6.71M | — |
| Diluted shares | — | 21.89M | 17.81M | 14.98M | 6.71M | — |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $6.17M | $738.00K | $227.00K | $13.97M | +736.7% |
| Cash & short-term investments | $6.17M | $738.00K | $227.00K | $13.97M | +736.7% |
| Accounts receivable | $4.65M | $13.56M | $10.05M | $4.45M | -65.7% |
| Inventory | $571.00K | $5.41M | $5.75M | $5.31M | -89.4% |
| Total current assets | $12.32M | $20.56M | $19.79M | $33.50M | -40.1% |
| Property, plant & equipment | $66.52M | $72.43M | $78.82M | $88.72M | -8.2% |
| Goodwill & intangibles | $15.10M | $16.59M | $18.35M | $240.69M | -9.0% |
| Total assets | $107.33M | $132.68M | $143.89M | $401.07M | -19.1% |
| Total current liabilities | $80.76M | $53.68M | $67.30M | $62.09M | +50.4% |
| Current debt | $14.00M | $6.36M | $39.24M | $37.60M | +120.1% |
| Long-term debt | — | $35.93M | — | — | — |
| Total debt | $40.90M | $68.84M | $65.42M | $65.59M | -40.6% |
| Total liabilities | $145.39M | $123.84M | $102.93M | $202.16M | +17.4% |
| Retained earnings | -$991.48M | -$899.68M | -$841.79M | -$645.50M | -10.2% |
| Shareholder equity | -$38.06M | $8.84M | $40.96M | $198.90M | -530.7% |
| Working capital | -$68.44M | -$33.12M | -$47.51M | -$28.59M | -106.6% |
| Net tangible assets | -$53.16M | -$7.76M | $22.61M | -$41.79M | -585.3% |
| Shares issued | 28.84M | 22.55M | 19.38M | 14.89M | +27.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$91.72M | -$57.89M | -$196.29M | $14.19M | — | -58.4% |
| Depreciation & amortisation | $7.29M | $7.92M | $9.32M | $9.44M | — | -7.9% |
| Stock-based compensation | $10.38M | $11.57M | $15.02M | $15.86M | — | -10.3% |
| Change in working capital | $33.59M | $22.20M | $3.25M | -$17.98M | — | +51.3% |
| Operating cash flow | -$13.25M | -$6.40M | -$38.69M | -$137.88M | — | -107.1% |
| Capital expenditure | — | -$161.00K | -$4.05M | -$5.24M | -$6.20M | — |
| Investing cash flow | $0 | $514.00K | -$4.05M | -$5.24M | — | -100.0% |
| Share buybacks | — | — | — | — | $0 | — |
| Dividends paid | -$5.90M | $0 | — | — | — | — |
| Financing cash flow | $18.65M | $6.70M | $24.09M | $119.84M | — | +178.3% |
| Free cash flow | -$13.25M | -$6.56M | -$42.73M | -$143.11M | — | -102.0% |
| End cash position | $16.37M | $10.98M | $10.16M | $28.80M | — | +49.1% |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $4.10M | $5.28M | $5.74M | $11.43M | $18.13M | -22.3% |
| Operating revenue | $4.10M | $5.28M | $5.74M | $11.43M | $18.13M | -22.3% |
| Cost of revenue | $7.37M | $3.90M | $5.24M | $3.55M | $7.34M | +88.9% |
| Gross profit | -$3.27M | $1.38M | $494.00K | $7.87M | $10.79M | -337.0% |
| Research & development | $3.35M | $4.60M | $3.35M | $3.73M | $3.83M | -27.2% |
| Selling, general & admin | $15.06M | $9.31M | $12.63M | $14.26M | $16.06M | +61.9% |
| Total operating expense | $18.79M | $14.28M | $16.36M | $18.36M | $20.26M | +31.6% |
| Operating income | -$22.06M | -$12.90M | -$15.86M | -$10.49M | -$9.47M | -71.0% |
| Net interest income | -$835.00K | -$1.42M | -$1.88M | -$2.36M | -$1.74M | +41.0% |
| Pre-tax income | -$24.36M | -$23.08M | -$24.52M | -$19.75M | -$13.29M | -5.6% |
| Tax provision | $3.00K | $0 | $0 | $0 | $0 | — |
| Net income | -$24.36M | -$23.08M | -$24.52M | -$19.75M | -$13.29M | -5.6% |
| Net income to common | -$24.45M | -$23.08M | -$24.52M | -$19.75M | -$13.29M | -5.9% |
| Basic EPS | — | -0.88 | -1.02 | -0.84 | — | — |
| Diluted EPS | — | -0.88 | -1.02 | -0.84 | — | — |
| EBIT | -$23.46M | -$21.60M | -$22.58M | -$17.32M | -$11.48M | -8.6% |
| EBITDA | -$21.66M | -$19.77M | -$20.75M | -$15.48M | -$9.61M | -9.5% |
| Basic shares | — | 26.35M | 24.02M | 23.53M | — | — |
| Diluted shares | — | 26.35M | 24.02M | 23.53M | — | — |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.17M | $120.00K | $863.00K | $293.00K | $738.00K | +5,045.8% |
| Cash & short-term investments | $6.17M | $120.00K | $863.00K | $293.00K | $738.00K | +5,045.8% |
| Accounts receivable | $4.65M | $6.71M | $11.15M | $14.97M | $13.56M | -30.6% |
| Inventory | $571.00K | $2.56M | $4.41M | $6.20M | $5.41M | -77.7% |
| Total current assets | $12.32M | $10.60M | $17.26M | $22.08M | $20.56M | +16.3% |
| Property, plant & equipment | $66.52M | $67.97M | $69.44M | $70.93M | $72.43M | -2.1% |
| Goodwill & intangibles | $15.10M | $15.48M | $15.86M | $16.23M | $16.59M | -2.4% |
| Total assets | $107.33M | $114.24M | $120.28M | $128.88M | $132.68M | -6.0% |
| Total current liabilities | $80.76M | $65.31M | $69.23M | $58.69M | $53.68M | +23.6% |
| Current debt | $14.00M | $4.28M | $6.95M | $6.65M | $6.36M | +226.9% |
| Long-term debt | — | — | $36.49M | $36.49M | $35.93M | — |
| Total debt | $40.90M | $66.76M | $70.15M | $69.78M | $68.84M | -38.7% |
| Total liabilities | $145.39M | $134.33M | $145.78M | $134.38M | $123.84M | +8.2% |
| Retained earnings | -$991.48M | -$967.10M | -$944.02M | -$919.50M | -$899.68M | -2.5% |
| Shareholder equity | -$38.06M | -$20.09M | -$25.50M | -$5.51M | $8.84M | -89.4% |
| Working capital | -$68.44M | -$54.72M | -$51.96M | -$36.61M | -$33.12M | -25.1% |
| Net tangible assets | -$53.16M | -$35.57M | -$41.35M | -$21.73M | -$7.76M | -49.5% |
| Shares issued | 28.84M | 28.22M | 24.61M | 23.94M | 22.55M | +2.2% |
| Line item | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$24.36M | -$23.08M | -$24.52M | -$19.75M | -$13.29M | -5.6% |
| Depreciation & amortisation | $1.80M | $1.82M | $1.83M | $1.83M | $1.88M | -1.2% |
| Stock-based compensation | $3.25M | $2.04M | $2.45M | $2.64M | $3.10M | +59.3% |
| Change in working capital | $7.86M | $6.69M | $14.76M | $4.29M | $9.75M | +17.6% |
| Operating cash flow | -$5.10M | -$4.16M | -$999.00K | -$2.99M | $1.59M | -22.7% |
| Capital expenditure | — | — | — | — | -$56.00K | — |
| Investing cash flow | $0 | $0 | $0 | $0 | -$1.56M | — |
| Dividends paid | $0 | — | — | — | — | — |
| Financing cash flow | $11.22M | $3.48M | $1.63M | $2.32M | $643.00K | +222.6% |
| Free cash flow | -$5.10M | -$4.16M | -$999.00K | -$2.99M | $1.54M | -22.7% |
| End cash position | $16.37M | $10.26M | $10.94M | $10.30M | $10.98M | +59.6% |
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
—
Positioning, not flow
Max pain
2.50
+212.5% from spot
ATM implied vol
50.0%
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
5
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
2.50
0 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2023 | -0.30 | -2.70 | -800.0% |
| Mar 2023 | -2.40 | -4.10 | -70.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $0 | — |
| Next quarter | — | — | $0 | — |
| Current year | — | — | $0 | — |
| Next year | — | — | $0 | — |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders37.18%
Held by institutions12.88%
Institutions holding42
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.72
+10.41% from price
SMA 20
0.71
+12.49% from price
SMA 50
0.72
+11.02% from price
SMA 100
0.88
-8.82% from price
SMA 200
1.15
-30.27% from price
EMA 12
0.74
+8.73% from price
EMA 26
0.73
+9.63% from price
EMA 50
0.76
+5.20% from price
RSI (14)
61.2
Neutral
MACD (12,26,9)
0.01
Hist 0.01
ATR (14)
0.07
8.74% of price
Realised vol 30D
64.0%
Annualised
Bollinger upper
0.79
20, 2σ
Bollinger lower
0.63
20, 2σ
50 / 200 cross
Death
0.72 vs 1.15
Trend bias
Below 200
-30.27%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.49
More volatile than market
Correlation to SPY
0.22
Largely independent
Realised vol 30D
64.0%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-84.8%
Peak to trough
Max drawdown 5Y
-99.5%
Peak to trough
ATR 14
0.07
8.74% of price
Beta (reported)
0.54
5Y monthly, from filing
Short interest
Shares short
390.84K
Prior 413.40K
Change vs prior
-5.5%
Shorts covering
% of float
5.87%
Normal
% of shares out
1.35%
Against total outstanding
Days to cover
4.1
Liquid
Float
18.87M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 25 | WBB Securities | UPGRADE | Hold | Buy |
| Aug 18, 25 | WBB Securities | INITIATED | — | Speculative Buy |
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:10
Split dateFeb 29, 2024
SEC filings
Periodic Financial Reports
NT 10-Q · 2026-08-14
Corporate Changes & Voting Matters
8-K · 2026-08-07
Corporate Changes & Voting Matters
8-K · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-06-30
Corporate Changes & Voting Matters
8-K · 2026-06-25
Corporate Changes & Voting Matters
8-K · 2026-06-12
Corporate Changes & Voting Matters
8-K · 2026-06-03
Corporate Changes & Voting Matters
8-K · 2026-05-28
Headlines
NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE
GlobeNewswire · 4d ago
NexGel Files to Register 15.25 Million Shares From Note Conversions
MT Newswires · 4d ago
NEXGEL Q2 Revenue Reaches $3.69 Million as BioNX Integration Faces Slower Ramp
InvestorsHub · 7d ago
NEXGEL Reports Second Quarter 2026 Financial Results
GlobeNewswire · 7d ago
Celularity Appoints Chief Operating Officer
MT Newswires · 59d ago
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies
GlobeNewswire · 81d ago
Celularity Releases CEO Letter to Shareholders
GlobeNewswire · 82d ago
Celularity Appoints Rick Gonzalez as Chief Commercial Officer
GlobeNewswire · 82d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.